Remnant-like particle-cholesterol concentrations in patients with type 2 diabetes mellitus and renal disease

Shaina Hirany, Dawn O'Byrne, Sridevi Devaraj, Ishwarlal Jialal

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Background: Lipid abnormalities contribute significantly to the increased risk of cardiovascular disease in diabetic and end-stage renal disease (ESRD) patients. Accumulating evidence supports a proatherogenic role for remnant lipoproteins. Thus, the aim of the present study was to compare remnant-like particle-cholesterol (RLP-C) in type 2 diabetic and ESRD patients with age- and gender-matched controls. Methods: Using an immunoaffinity assay, we measured RLP-C concentrations in 48 type 2 diabetic patients with (n = 24) and without (n = 24) macrovascular complications, and 24 age- and gender-matched controls, as well as in 38 ESRD patients on hemodialysis (n = 19) and peritoneal dialysis (n = 19), and 19 age- and gender-matched controls. Results: RLP-C correlated significantly with plasma triglycerides (TGs; r = 0.8). When compared with controls, RLP-C concentrations were significantly higher in type 2 diabetic patients with and without macrovascular complications (median, 0.22 and 0.17 mmol/L vs 0.14 mmol/L; P <0.0002 and <0.01, respectively); diabetic patients with macrovascular complications also had significantly higher RLP-C than diabetic patients without macrovascular complications (P <0.05). However, when RLP- C/TG ratios were computed, only diabetic patients with macrovascular complications showed significantly higher RLP-C/TG ratios compared with controls (P <0.05). Regarding ESRD, RLP-C concentrations were significantly increased in patients on both hemodialysis and peritoneal dialysis compared with controls (median, 0.23 and 0.21 mmol/L vs 0.13 mmol/L; P <0.0001). Whereas RLP-C was increased in ESRD patients on hemodialysis with TGs <2.26 mmol/L compared with controls, RLP-C/TG ratios were not significantly increased in these patients. Conclusions: Type 2 diabetic patients with macrovascular disease demonstrated increased RLP-C and RLPC/TG ratios, whereas ESRD patients showed only increased RLP-C concentrations. (C) 2000 American Association for Clinical Chemistry.

Original languageEnglish (US)
Pages (from-to)667-672
Number of pages6
JournalClinical Chemistry
Volume46
Issue number5
StatePublished - 2000
Externally publishedYes

Fingerprint

Medical problems
Type 2 Diabetes Mellitus
Kidney
Chronic Kidney Failure
Dialysis
Renal Dialysis
Peritoneal Dialysis
remnant-like particle cholesterol
Lipoproteins
Assays
Triglycerides
Cardiovascular Diseases
Lipids
Plasmas

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Remnant-like particle-cholesterol concentrations in patients with type 2 diabetes mellitus and renal disease. / Hirany, Shaina; O'Byrne, Dawn; Devaraj, Sridevi; Jialal, Ishwarlal.

In: Clinical Chemistry, Vol. 46, No. 5, 2000, p. 667-672.

Research output: Contribution to journalArticle

Hirany, S, O'Byrne, D, Devaraj, S & Jialal, I 2000, 'Remnant-like particle-cholesterol concentrations in patients with type 2 diabetes mellitus and renal disease', Clinical Chemistry, vol. 46, no. 5, pp. 667-672.
Hirany, Shaina ; O'Byrne, Dawn ; Devaraj, Sridevi ; Jialal, Ishwarlal. / Remnant-like particle-cholesterol concentrations in patients with type 2 diabetes mellitus and renal disease. In: Clinical Chemistry. 2000 ; Vol. 46, No. 5. pp. 667-672.
@article{c1bec541d6ac4f358f7757908773819d,
title = "Remnant-like particle-cholesterol concentrations in patients with type 2 diabetes mellitus and renal disease",
abstract = "Background: Lipid abnormalities contribute significantly to the increased risk of cardiovascular disease in diabetic and end-stage renal disease (ESRD) patients. Accumulating evidence supports a proatherogenic role for remnant lipoproteins. Thus, the aim of the present study was to compare remnant-like particle-cholesterol (RLP-C) in type 2 diabetic and ESRD patients with age- and gender-matched controls. Methods: Using an immunoaffinity assay, we measured RLP-C concentrations in 48 type 2 diabetic patients with (n = 24) and without (n = 24) macrovascular complications, and 24 age- and gender-matched controls, as well as in 38 ESRD patients on hemodialysis (n = 19) and peritoneal dialysis (n = 19), and 19 age- and gender-matched controls. Results: RLP-C correlated significantly with plasma triglycerides (TGs; r = 0.8). When compared with controls, RLP-C concentrations were significantly higher in type 2 diabetic patients with and without macrovascular complications (median, 0.22 and 0.17 mmol/L vs 0.14 mmol/L; P <0.0002 and <0.01, respectively); diabetic patients with macrovascular complications also had significantly higher RLP-C than diabetic patients without macrovascular complications (P <0.05). However, when RLP- C/TG ratios were computed, only diabetic patients with macrovascular complications showed significantly higher RLP-C/TG ratios compared with controls (P <0.05). Regarding ESRD, RLP-C concentrations were significantly increased in patients on both hemodialysis and peritoneal dialysis compared with controls (median, 0.23 and 0.21 mmol/L vs 0.13 mmol/L; P <0.0001). Whereas RLP-C was increased in ESRD patients on hemodialysis with TGs <2.26 mmol/L compared with controls, RLP-C/TG ratios were not significantly increased in these patients. Conclusions: Type 2 diabetic patients with macrovascular disease demonstrated increased RLP-C and RLPC/TG ratios, whereas ESRD patients showed only increased RLP-C concentrations. (C) 2000 American Association for Clinical Chemistry.",
author = "Shaina Hirany and Dawn O'Byrne and Sridevi Devaraj and Ishwarlal Jialal",
year = "2000",
language = "English (US)",
volume = "46",
pages = "667--672",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "5",

}

TY - JOUR

T1 - Remnant-like particle-cholesterol concentrations in patients with type 2 diabetes mellitus and renal disease

AU - Hirany, Shaina

AU - O'Byrne, Dawn

AU - Devaraj, Sridevi

AU - Jialal, Ishwarlal

PY - 2000

Y1 - 2000

N2 - Background: Lipid abnormalities contribute significantly to the increased risk of cardiovascular disease in diabetic and end-stage renal disease (ESRD) patients. Accumulating evidence supports a proatherogenic role for remnant lipoproteins. Thus, the aim of the present study was to compare remnant-like particle-cholesterol (RLP-C) in type 2 diabetic and ESRD patients with age- and gender-matched controls. Methods: Using an immunoaffinity assay, we measured RLP-C concentrations in 48 type 2 diabetic patients with (n = 24) and without (n = 24) macrovascular complications, and 24 age- and gender-matched controls, as well as in 38 ESRD patients on hemodialysis (n = 19) and peritoneal dialysis (n = 19), and 19 age- and gender-matched controls. Results: RLP-C correlated significantly with plasma triglycerides (TGs; r = 0.8). When compared with controls, RLP-C concentrations were significantly higher in type 2 diabetic patients with and without macrovascular complications (median, 0.22 and 0.17 mmol/L vs 0.14 mmol/L; P <0.0002 and <0.01, respectively); diabetic patients with macrovascular complications also had significantly higher RLP-C than diabetic patients without macrovascular complications (P <0.05). However, when RLP- C/TG ratios were computed, only diabetic patients with macrovascular complications showed significantly higher RLP-C/TG ratios compared with controls (P <0.05). Regarding ESRD, RLP-C concentrations were significantly increased in patients on both hemodialysis and peritoneal dialysis compared with controls (median, 0.23 and 0.21 mmol/L vs 0.13 mmol/L; P <0.0001). Whereas RLP-C was increased in ESRD patients on hemodialysis with TGs <2.26 mmol/L compared with controls, RLP-C/TG ratios were not significantly increased in these patients. Conclusions: Type 2 diabetic patients with macrovascular disease demonstrated increased RLP-C and RLPC/TG ratios, whereas ESRD patients showed only increased RLP-C concentrations. (C) 2000 American Association for Clinical Chemistry.

AB - Background: Lipid abnormalities contribute significantly to the increased risk of cardiovascular disease in diabetic and end-stage renal disease (ESRD) patients. Accumulating evidence supports a proatherogenic role for remnant lipoproteins. Thus, the aim of the present study was to compare remnant-like particle-cholesterol (RLP-C) in type 2 diabetic and ESRD patients with age- and gender-matched controls. Methods: Using an immunoaffinity assay, we measured RLP-C concentrations in 48 type 2 diabetic patients with (n = 24) and without (n = 24) macrovascular complications, and 24 age- and gender-matched controls, as well as in 38 ESRD patients on hemodialysis (n = 19) and peritoneal dialysis (n = 19), and 19 age- and gender-matched controls. Results: RLP-C correlated significantly with plasma triglycerides (TGs; r = 0.8). When compared with controls, RLP-C concentrations were significantly higher in type 2 diabetic patients with and without macrovascular complications (median, 0.22 and 0.17 mmol/L vs 0.14 mmol/L; P <0.0002 and <0.01, respectively); diabetic patients with macrovascular complications also had significantly higher RLP-C than diabetic patients without macrovascular complications (P <0.05). However, when RLP- C/TG ratios were computed, only diabetic patients with macrovascular complications showed significantly higher RLP-C/TG ratios compared with controls (P <0.05). Regarding ESRD, RLP-C concentrations were significantly increased in patients on both hemodialysis and peritoneal dialysis compared with controls (median, 0.23 and 0.21 mmol/L vs 0.13 mmol/L; P <0.0001). Whereas RLP-C was increased in ESRD patients on hemodialysis with TGs <2.26 mmol/L compared with controls, RLP-C/TG ratios were not significantly increased in these patients. Conclusions: Type 2 diabetic patients with macrovascular disease demonstrated increased RLP-C and RLPC/TG ratios, whereas ESRD patients showed only increased RLP-C concentrations. (C) 2000 American Association for Clinical Chemistry.

UR - http://www.scopus.com/inward/record.url?scp=0034113662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034113662&partnerID=8YFLogxK

M3 - Article

VL - 46

SP - 667

EP - 672

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 5

ER -